Since the first reported human infection with SARS-CoV-2 in December 2019, many protein subunit vaccines have been proposed for human use. Subunit vaccines Use one or more antigens suitable for eliciting a robust immune response. However, the main concern is the effectiveness of subunit vaccines and elicited antibodies to neutralize variants of SARS-CoV-2 such as B.1.1.7 (alpha), B.1.351 (beta) and P1 (gamma), B.1.617 ( Delta) and C.37 (Lambda). The spike protein (S) is a potential fragment for use as an antigen … Continue reading „SARS-CoV-2 Spike P681H Antikörper (Alpha, Mu-Variante)“